Role of combined Testing of Serum Tumor Markers in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.

傅德良,倪泉兴,虞先浚,华宇明,徐近,陈炜,张群华,张延龄
DOI: https://doi.org/10.3969/j.issn.1007-9610.2001.02.007
2001-01-01
Abstract:To assess the value of combined testing of serum tumor markers inthe diagnosis and treatment of pancreatic carcinoma. Methods: Detection of 8 serum tumor markers, including AFP, CEA, CA50, CA15-3, CA19-9, CA72-4, CA125 and CA242, was carried out in 95 patients with pancreatic carcinoma by auto time-resolved fluorometric assay(ATRFMA) and immunoradiometric assay(IRMA); 70 patients with other malignant tumors, 73 patients with benign disease and 25 patients following pancreatectomy were studied at the same time. Results: Among the 8 tumor markers, CA19-9, CA242, CA50 and CA125 were more valuable in the diagnosis of pancreatic carcinoma. Method of parallel combined testing could increase the diagnostic sensitivity to 90.2%, and serial combined examination could increase the diagnostic specificity to 93.5%. The expression of tumor markers did not undergo any obvious change after intervention chemotherapy, but decreased significantly after radical tumor resection. Conclusions: Serum CA19-9, CA242, CA50 and CA125 were the preferred tumor markers to be used in the diagnosis and the follow-up of operated cases of pancreatic carcinoma. Combined testing could increase the sensitivity and specificity in diagnosing pancreatic carcinoma.
What problem does this paper attempt to address?